D. Boral Capital Reiterates Hold Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

D. Boral Capital restated their hold rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research report report published on Friday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $0.22 on Friday. The firm has a market capitalization of $40.01 million, a price-to-earnings ratio of -0.56 and a beta of 1.66. The stock has a fifty day moving average of $0.40 and a 200 day moving average of $0.58. Citius Pharmaceuticals has a 52-week low of $0.11 and a 52-week high of $1.07.

Shares of Citius Pharmaceuticals are set to reverse split before the market opens on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 25th.

Institutional Trading of Citius Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CTXR. Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals during the second quarter valued at approximately $29,000. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the 3rd quarter valued at $47,000. Virtu Financial LLC bought a new position in shares of Citius Pharmaceuticals during the 3rd quarter valued at $50,000. Miller Investment Management LP raised its position in Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in Citius Pharmaceuticals in the second quarter worth $69,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.